{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:20:00Z","timestamp":1781076000392,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024YFFK0025"],"award-info":[{"award-number":["2024YFFK0025"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04247-2","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T11:15:25Z","timestamp":1746789325000},"page":"466-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of thyroglobulin changes on clinical outcomes of differentiated thyroid cancer with biochemical incomplete response"],"prefix":"10.1007","volume":"89","author":[{"given":"Xiaohui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3191-0528","authenticated-orcid":false,"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"1","key":"4247_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"R.L. Siegel, K.D. Miller, N.S. Wagle, A. Jemal, Cancer statistics, 2023. CA Cancer J. Clin. 73(1), 17\u201348 (2023). https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"4247_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"B. Han, R. Zheng, H. Zeng, S. Wang, K. Sun et al., Cancer incidence and mortality in China, 2022. J. Natl Cancer Cent. 4(1), 47\u201353 (2024). https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006.","journal-title":"J. Natl Cancer Cent."},{"issue":"3","key":"4247_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209\u2013249 (2021). https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"4247_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/s2213-8587(22)00035-3","volume":"10","author":"M Pizzato","year":"2022","unstructured":"M. Pizzato, M. Li, J. Vignat, M. Laversanne, D. Singh et al., The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 10(4), 264\u2013272 (2022). https:\/\/doi.org\/10.1016\/s2213-8587(22)00035-3.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"4247_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2967\/jnumed.119.240945","volume":"61","author":"KJ Donohoe","year":"2020","unstructured":"K.J. Donohoe, J. Aloff, A.M. Avram, K.G. Bennet, L. Giovanella et al., Appropriate use criteria for nuclear medicine in the evaluation and treatment of differentiated thyroid cancer. J. Nucl. Med. 61(3), 375\u2013396 (2020). https:\/\/doi.org\/10.2967\/jnumed.119.240945.","journal-title":"J. Nucl. Med."},{"issue":"1","key":"4247_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel et al., 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1\u2013133 (2016). https:\/\/doi.org\/10.1089\/thy.2015.0020.","journal-title":"Thyroid"},{"issue":"12","key":"4247_CR7","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/thy.2010.0178","volume":"20","author":"RM Tuttle","year":"2010","unstructured":"R.M. Tuttle, H. Tala, J. Shah, R. Leboeuf, R. Ghossein et al., Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging system. Thyroid 20(12), 1341\u20131349 (2010). https:\/\/doi.org\/10.1089\/thy.2010.0178.","journal-title":"Thyroid"},{"issue":"3","key":"4247_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1530\/eje-11-0466","volume":"165","author":"MG Castagna","year":"2011","unstructured":"M.G. Castagna, F. Maino, C. Cipri, V. Belardini, A. Theodoropoulou et al., Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur. J. Endocrinol. 165(3), 441\u2013446 (2011). https:\/\/doi.org\/10.1530\/eje-11-0466.","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"4247_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1365-2265.2012.04342.x","volume":"77","author":"F Vaisman","year":"2012","unstructured":"F. Vaisman, D. Momesso, D.A. Bulzico, C.H. Pessoa, F. Dias et al., Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin. Endocrinol. 77(1), 132\u2013138 (2012). https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04342.x.","journal-title":"Clin. Endocrinol."},{"key":"4247_CR10","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1210\/clinem\/dgad748","volume":"109","author":"BH Kim","year":"2023","unstructured":"B.H. Kim, S.R. Ryu, J.W. Lee, C.M. Song, Y.B. Ji et al., Longitudinal changes in quality of life before and after thyroidectomy in patients with differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 109, 1505\u20131516 (2023). https:\/\/doi.org\/10.1210\/clinem\/dgad748.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4247_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.20945\/2359-3997000000461","volume":"66","author":"R do Prado Padovani","year":"2022","unstructured":"R. do Prado Padovani, S.V. Chablani, R.M. Tuttle, Radioactive iodine therapy: multiple faces of the same polyhedron. Arch. Endocrinol. Metab. 66(3), 393\u2013406 (2022). https:\/\/doi.org\/10.20945\/2359-3997000000461.","journal-title":"Arch. Endocrinol. Metab."},{"issue":"4","key":"4247_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jamaoto.2014.1","volume":"140","author":"L Davies","year":"2014","unstructured":"L. Davies, H.G. Welch, Current thyroid cancer trends in the United States. JAMA Otolaryngol. Head. Neck Surg. 140(4), 317\u2013322 (2014). https:\/\/doi.org\/10.1001\/jamaoto.2014.1.","journal-title":"JAMA Otolaryngol. Head. Neck Surg."},{"issue":"2","key":"4247_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1210\/clinem\/dgac646","volume":"108","author":"TM Ullmann","year":"2023","unstructured":"T.M. Ullmann, M. Papaleontiou, J.A. Sosa, Current controversies in low-risk differentiated thyroid cancer: reducing overtreatment in an era of overdiagnosis. J. Clin. Endocrinol. Metab. 108(2), 271\u2013280 (2023). https:\/\/doi.org\/10.1210\/clinem\/dgac646.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"4247_CR14","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1245\/s10434-017-5911-6","volume":"24","author":"NK Zern","year":"2017","unstructured":"N.K. Zern, R. Clifton-Bligh, A.J. Gill, A. Aniss, S. Sidhu et al., Disease progression in papillary thyroid cancer with biochemical incomplete response to initial therapy. Ann. Surg. Oncol. 24(9), 2611\u20132616 (2017). https:\/\/doi.org\/10.1245\/s10434-017-5911-6.","journal-title":"Ann. Surg. Oncol."},{"issue":"8","key":"4247_CR15","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s00268-020-05521-2","volume":"44","author":"S Enumah","year":"2020","unstructured":"S. Enumah, A. Fingeret, S. Parangi, D. Dias-Santagata, P.M. Sadow et al., BRAF(V600E) mutation is associated with an increased risk of papillary thyroid cancer recurrence. World J. Surg. 44(8), 2685\u20132691 (2020). https:\/\/doi.org\/10.1007\/s00268-020-05521-2.","journal-title":"World J. Surg."},{"issue":"21","key":"4247_CR16","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.3390\/cancers13215422","volume":"13","author":"M Steinschneider","year":"2021","unstructured":"M. Steinschneider, J. Pitaro, S. Koren, Y. Mizrakli, C. Benbassat et al., Differentiated thyroid cancer with biochemical incomplete response: clinico-pathological characteristics and long term disease outcomes. Cancers 13(21), 5422 (2021). https:\/\/doi.org\/10.3390\/cancers13215422.","journal-title":"Cancers"},{"issue":"1","key":"4247_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12020-021-02976-8","volume":"76","author":"Y Wang","year":"2022","unstructured":"Y. Wang, J. Wu, L. Jiang, X. Zhang, B. Liu, Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a Bi-Center Observational Study. Endocrine 76(1), 109\u2013115 (2022). https:\/\/doi.org\/10.1007\/s12020-021-02976-8.","journal-title":"Endocrine"},{"issue":"7","key":"4247_CR18","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1089\/thy.2019.0585","volume":"30","author":"L Liu","year":"2020","unstructured":"L. Liu, X. Zhang, T. Tian, R. Huang, B. Liu, Prognostic value of pre-ablation stimulated thyroglobulin in children and adolescents with differentiated thyroid cancer. Thyroid 30(7), 1017\u20131024 (2020). https:\/\/doi.org\/10.1089\/thy.2019.0585.","journal-title":"Thyroid"},{"issue":"4","key":"4247_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1089\/thy.2016.0479","volume":"27","author":"FC Shen","year":"2017","unstructured":"F.C. Shen, C.J. Hsieh, I.C. Huang, Y.H. Chang, P.W. Wang, Dynamic risk estimates of outcome in Chinese patients with well-differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation. Thyroid 27(4), 531\u2013536 (2017). https:\/\/doi.org\/10.1089\/thy.2016.0479.","journal-title":"Thyroid"},{"issue":"3","key":"4247_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1210\/jc.2016-2860","volume":"102","author":"A Matrone","year":"2017","unstructured":"A. Matrone, C. Gambale, P. Piaggi, D. Viola, C. Giani et al., Postoperative thyroglobulin and neck ultrasound in the risk restratification and decision to perform 131I ablation. J. Clin. Endocrinol. Metab. 102(3), 893\u2013902 (2017). https:\/\/doi.org\/10.1210\/jc.2016-2860.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"4247_CR21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/mnm.0000000000001154","volume":"41","author":"X Zhang","year":"2020","unstructured":"X. Zhang, T. Higuchi, H. Tomonaga, O. Lamid-Ochir, A. Bhattarai et al., Early detection of progressive disease using thyroglobulin doubling-time in metastatic differentiated thyroid carcinoma treated with radioactive iodine. Nucl. Med. Commun. 41(4), 350\u2013355 (2020). https:\/\/doi.org\/10.1097\/mnm.0000000000001154.","journal-title":"Nucl. Med. Commun."},{"issue":"12","key":"4247_CR22","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1089\/thy.2016.0031","volume":"26","author":"RM R\u00f6ssing","year":"2016","unstructured":"R.M. R\u00f6ssing, W. Jentzen, J. Nagarajah, A. Bockisch, R. G\u00f6rges, Serum thyroglobulin doubling time in progressive thyroid cancer. Thyroid 26(12), 1712\u20131718 (2016). https:\/\/doi.org\/10.1089\/thy.2016.0031.","journal-title":"Thyroid"},{"issue":"8","key":"4247_CR23","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1210\/jc.2018-02680","volume":"104","author":"B Barres","year":"2019","unstructured":"B. Barres, A. Kelly, F. Kwiatkowski, M. Batisse-Lignier, G. Fouilhoux et al., Stimulated thyroglobulin and thyroglobulin reduction index predict excellent response in differentiated thyroid cancers. J. Clin. Endocrinol. Metab. 104(8), 3462\u20133472 (2019). https:\/\/doi.org\/10.1210\/jc.2018-02680.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4247_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s12020-019-02142-1","volume":"67","author":"J Ahn","year":"2020","unstructured":"J. Ahn, E. Song, W.G. Kim, T.Y. Kim, W.B. Kim et al., Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response. Endocrine 67(3), 623\u2013629 (2020). https:\/\/doi.org\/10.1007\/s12020-019-02142-1.","journal-title":"Endocrine"},{"key":"4247_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/398194","volume":"2013","author":"F Vaisman","year":"2013","unstructured":"F. Vaisman, D. Momesso, D.A. Bulzico, C.H. Pessoa, da, M.D. Cruz et al., Thyroid lobectomy is associated with excellent clinical outcomes in properly selected differentiated thyroid cancer patients with primary tumors greater than 1\u2009cm. J. Thyroid. Res. 2013, 398194 (2013). https:\/\/doi.org\/10.1155\/2013\/398194.","journal-title":"J. Thyroid. Res."},{"key":"4247_CR26","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.2147\/cmar.S320993","volume":"13","author":"ST Lim","year":"2021","unstructured":"S.T. Lim, Y.W. Jeon, H. Gwak, J.S. Bae, Y.J. Suh, Nomogram for the prediction of biochemical incomplete response in papillary thyroid cancer patients. Cancer Manag. Res. 13, 5641\u20135650 (2021). https:\/\/doi.org\/10.2147\/cmar.S320993.","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"4247_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1148\/radiol.14132234","volume":"273","author":"B Liu","year":"2014","unstructured":"B. Liu, W. Peng, R. Huang, R. Tian, Y. Zeng et al., Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements. Radiology 273(1), 211\u2013219 (2014). https:\/\/doi.org\/10.1148\/radiol.14132234.","journal-title":"Radiology"},{"key":"4247_CR28","unstructured":"M.B. Amin, S.B. Edge, F.L. Greene, D.R. Byrd, R.K. Brookland et al. AJCC cancer staging manual (New York, Springer, 2017). https:\/\/link.springer.com\/book\/9783319406176."},{"issue":"3","key":"4247_CR29","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1210\/jc.2002-021365","volume":"88","author":"E Baudin","year":"2003","unstructured":"E. Baudin, C. Do Cao, A.F. Cailleux, S. Leboulleux, J.P. Travagli et al., Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J. Clin. Endocrinol. Metab. 88(3), 1107\u20131111 (2003). https:\/\/doi.org\/10.1210\/jc.2002-021365.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4247_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1210\/jc.2017-01790","volume":"103","author":"D Hirsch","year":"2018","unstructured":"D. Hirsch, A. Gorshtein, E. Robenshtok, H. Masri-Iraqi, A. Akirov et al., Second radioiodine treatment: limited benefit for differentiated thyroid cancer with locoregional persistent disease. J. Clin. Endocrinol. Metab. 103(2), 469\u2013476 (2018). https:\/\/doi.org\/10.1210\/jc.2017-01790.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"4247_CR31","doi-asserted-by":"publisher","DOI":"10.1530\/etj-23-0052","volume":"12","author":"C Gambale","year":"2023","unstructured":"C. Gambale, A. Prete, L. Contartese, L. Torregrossa, F. Bianchi et al., Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients. Eur. Thyroid. J. 12(6), e230052 (2023). https:\/\/doi.org\/10.1530\/etj-23-0052.","journal-title":"Eur. Thyroid. J."},{"issue":"12","key":"4247_CR32","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1089\/thy.2011.0232","volume":"21","author":"F Vaisman","year":"2011","unstructured":"F. Vaisman, H. Tala, R. Grewal, R.M. Tuttle, In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid 21(12), 1317\u20131322 (2011). https:\/\/doi.org\/10.1089\/thy.2011.0232.","journal-title":"Thyroid"},{"issue":"6","key":"4247_CR33","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1089\/thy.2019.0431","volume":"30","author":"I Moreno","year":"2020","unstructured":"I. Moreno, D. Hirsch, H. Duskin-Bitan, T. Dicker-Cohen, I. Shimon et al., Response to therapy assessment in intermediate-risk thyroid cancer patients: is thyroglobulin stimulation required?. Thyroid 30(6), 863\u2013870 (2020). https:\/\/doi.org\/10.1089\/thy.2019.0431.","journal-title":"Thyroid"},{"issue":"11","key":"4247_CR34","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.3390\/cancers15112976","volume":"15","author":"A Signore","year":"2023","unstructured":"A. Signore, C. Lauri, A. Di Paolo, V. Stati, G. Santolamazza et al., Predictive role of serum thyroglobulin after surgery and before radioactive iodine therapy in patients with thyroid carcinoma. Cancers 15(11), 2976 (2023). https:\/\/doi.org\/10.3390\/cancers15112976.","journal-title":"Cancers"},{"key":"4247_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.587315","volume":"11","author":"R Sa","year":"2020","unstructured":"R. Sa, L. Cheng, Y. Jin, H. Fu, Y. Shen et al., Distinguishing patients with distant metastatic differentiated thyroid cancer who biochemically benefit from next radioiodine treatment. Front. Endocrinol. 11, 587315 (2020). https:\/\/doi.org\/10.3389\/fendo.2020.587315.","journal-title":"Front. Endocrinol."},{"issue":"2","key":"4247_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/cancers13020310","volume":"13","author":"S Szujo","year":"2021","unstructured":"S. Szujo, L. Bajnok, B. Bodis, Z. Nagy, O. Nemes et al., The prognostic role of postablative non-stimulated thyroglobulin in differentiated thyroid cancer. Cancers 13(2), 310 (2021). https:\/\/doi.org\/10.3390\/cancers13020310.","journal-title":"Cancers"},{"issue":"8","key":"4247_CR37","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1210\/jc.2012-1123","volume":"97","author":"C Durante","year":"2012","unstructured":"C. Durante, T. Montesano, M. Attard, M. Torlontano, F. Monzani et al., Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?. J. Clin. Endocrinol. Metab. 97(8), 2748\u20132753 (2012). https:\/\/doi.org\/10.1210\/jc.2012-1123.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"4247_CR38","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1089\/thy.2011.0522","volume":"22","author":"RP Padovani","year":"2012","unstructured":"R.P. Padovani, E. Robenshtok, M. Brokhin, R.M. Tuttle, Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid 22(8), 778\u2013783 (2012). https:\/\/doi.org\/10.1089\/thy.2011.0522.","journal-title":"Thyroid"},{"issue":"3","key":"4247_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3881\/j.issn.1000-503X.2016.03.020","volume":"38","author":"CX Li","year":"2016","unstructured":"C.X. Li, M. Hou, C. Ren, Y.S. Lin, Serial thyroglobulin variation trend shortly after radioiodine therapy in poorly to moderately differentiated recurrent thyroid cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 38(3), 351\u2013355 (2016). https:\/\/doi.org\/10.3881\/j.issn.1000-503X.2016.03.020.","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"issue":"3","key":"4247_CR40","doi-asserted-by":"publisher","first-page":"518","DOI":"10.20471\/acc.2018.57.03.16","volume":"57","author":"M Prpi\u0107","year":"2018","unstructured":"M. Prpi\u0107, M. Franceschi, M. Romi\u0107, T. Juki\u0107, Z. Kusi\u0107, Thyroglobulin as a tumor marker in differentiated thyroid cancer - clinical considerations. Acta Clin. Croat. 57(3), 518\u2013527 (2018). https:\/\/doi.org\/10.20471\/acc.2018.57.03.16.","journal-title":"Acta Clin. Croat."},{"issue":"5","key":"4247_CR41","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1210\/jc.2010-2708","volume":"96","author":"M Brassard","year":"2011","unstructured":"M. Brassard, I. Borget, A. Edet-Sanson, A.L. Giraudet, O. Mundler et al., Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J. Clin. Endocrinol. Metab. 96(5), 1352\u20131359 (2011). https:\/\/doi.org\/10.1210\/jc.2010-2708.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"4247_CR42","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1530\/eje.0.1410460","volume":"141","author":"J B\u00f6hm","year":"1999","unstructured":"J. B\u00f6hm, V.M. Kosma, M. Eskelinen, S. Hollmen, M. Niskanen et al., Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma. Eur. J. Endocrinol. 141(5), 460\u2013467 (1999). https:\/\/doi.org\/10.1530\/eje.0.1410460.","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"4247_CR43","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/mnm.0000000000000796","volume":"39","author":"HY Hu","year":"2018","unstructured":"H.Y. Hu, J. Liang, T. Zhang, T. Zhao, Y.S. Lin, Suppressed thyroglobulin performs better than stimulated thyroglobulin in defining an excellent response in patients with differentiated thyroid cancer. Nucl. Med. Commun. 39(3), 247\u2013251 (2018). https:\/\/doi.org\/10.1097\/mnm.0000000000000796.","journal-title":"Nucl. Med. Commun."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04247-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04247-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04247-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:11:46Z","timestamp":1753369906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04247-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4247"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04247-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the Institutional Review Board of Sichuan University, West China Hospital, and the requirement for obtaining written informed consent from the patients was waived. The ethical committee approval number is 2023-2091.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}